Clearside's Zuprata reduces Eylea need in Phase II trial

Clearside Biomedical Inc. (Alpharetta, Ga.) said Zuprata ( CLS-TA) reduced the need for injections of Eylea aflibercept in the Phase II Tanzanite trial to treat macular edema associated with retinal vein occlusion (RVO), meeting the study's primary endpoint. Patients receiving a single suprachoroidal injection of Zuprata plus intravitreal Eylea required 60% fewer additional Eylea treatments over three months than those receiving Eylea alone (p=0.013), the company said.

CFO Charles Deignan told BioCentury the combo met two secondary endpoints of improving best corrected visual acuity (BCVA) and reducing central subfield thickness vs. Eylea alone. Zuprata is triamcinolone acetonide delivered using the company's suprachoroidal space microinjector. ...